Zhejiang Qizheng Pharmaceutical’s Ruxolitinib Phosphate Tablets Approved for Marketing, Marking Another Milestone in Its Integrated Value Chain Strategy
Recently, Zhejiang Qizheng Pharmaceutical Co., Ltd. (“Qizheng Pharmaceutical”) achieved an important milestone in R&D and industrialization with the receipt of the Drug Registration Certificate for Ruxolitinib Phosphate Tablets, approved and issued by China’s National Medical Products Administration (NMPA).
The approval means that the product is deemed to have passed the generic drug quality and efficacy consistency evaluation, further demonstrating Qizheng Pharmaceutical’s formulation R&D capabilities in the fields of hematologic oncology and immunomodulation.
Addressing Clinical Needs and Expanding Treatment Options for Serious Diseases
Ruxolitinib phosphate is a potent and selective Janus kinase (JAK) 1/2 inhibitor. The approved indications cover multiple disease areas of significant clinical importance:
- Myelofibrosis: For the treatment of disease-related splenomegaly and symptoms in adult patients with intermediate- or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF).
- Graft-versus-Host Disease (GVHD): For the treatment of corticosteroid-refractory acute and chronic graft-versus-host disease.
- Autoimmune Disease: For the treatment of non-segmental vitiligo with facial involvement in patients aged 12 years and older.
As a globally recognized blockbuster drug, ruxolitinib phosphate has demonstrated substantial market potential and significant therapeutic value. According to IQVIA data, global sales of the drug reached approximately USD 4.728 billion in 2024. The successful approval of Qizheng Pharmaceutical’s Ruxolitinib Phosphate Tablets is expected to provide patients in China with additional high-quality and more accessible treatment options.
Advancing an Integrated Value Chain Strategy and Strengthening Core Competitiveness
As a wholly owned subsidiary of Ausun Pharmaceutical (Stock Code: 603229), a company listed on the Main Board of the Shanghai Stock Exchange, and a core platform for finished dosage form development and industrialization, Qizheng Pharmaceutical has invested substantial human and material resources over the years in advancing the R&D and industrialization of pharmaceutical formulations.
The receipt of the Drug Registration Certificate not only reflects the dedication and perseverance of Qizheng Pharmaceutical’s R&D team, but also represents another important milestone in Ausun Pharmaceutical’s integrated strategy encompassing “intermediates + specialty APIs + finished dosage forms.”
Through integrated value-chain synergies, Qizheng Pharmaceutical is able to maintain stringent quality control and supply-chain stability from upstream key raw materials through to downstream finished dosage forms, further strengthening its core competitiveness and operational resilience in the finished dosage form business.
Looking ahead, Qizheng Pharmaceutical will remain committed to its philosophy of “patient-centricity and quality first.” Leveraging its robust R&D platform and industrialization capabilities, the company will accelerate the commercialization of key products as well as the development and regulatory filing of additional high-quality pharmaceutical products, contributing to the high-quality development of China’s pharmaceutical and healthcare industry.
Keywords:
Previous page
Related News
Pharmacovigilance
Tel:+86-576-88113608
Email:pv@kisunpharm.net
Let's stay in touch and keep up with the company's latest updates.
